UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus

Loading...
Loading...
Stifel Nicolaus initiated its coverage on Oncolytics Ciotech
ONCY
with a Buy rating and a price target of $6 a share. Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy." Oncolytics Ciotech closed at $2.76 on Wednesday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetInitiationIntraday UpdateAnalyst RatingsStifel Nicolaus
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...